Lisa Hamilton

ORCID: 0009-0004-4493-5614
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Breast Lesions and Carcinomas
  • Breast Cancer Treatment Studies
  • Cancer and Skin Lesions
  • Lipoproteins and Cardiovascular Health
  • Digital Radiography and Breast Imaging
  • Salivary Gland Tumors Diagnosis and Treatment
  • Erythropoietin and Anemia Treatment
  • Medical Imaging Techniques and Applications
  • Cancer Diagnosis and Treatment
  • AI in cancer detection
  • Iron Metabolism and Disorders
  • Chronic Lymphocytic Leukemia Research
  • Bone health and treatments
  • Bone health and osteoporosis research
  • Soft tissue tumor case studies
  • Migraine and Headache Studies
  • Antibiotics Pharmacokinetics and Efficacy
  • Pharmaceutical studies and practices
  • Underground infrastructure and sustainability
  • Advanced X-ray and CT Imaging
  • Geotechnical Engineering and Analysis
  • Hemoglobinopathies and Related Disorders
  • BRCA gene mutations in cancer
  • Global Cancer Incidence and Screening
  • Bariatric Surgery and Outcomes

University of Arizona
2025

Mount Sinai Hospital
1996-2022

Sherwood Forest Hospitals NHS Foundation Trust
2021

NHS Tayside
2021

Amgen (United Kingdom)
2007-2019

Nottingham University Hospitals NHS Trust
2008-2016

University of Nottingham
2004-2015

Bassett Healthcare Network
2015

University of Colorado Denver
2015

Seattle University
2014

Monoclonal antibodies (mAbs) targeting calcitonin gene‐related peptide (CGRP) signaling are being explored as prophylactic treatments for migraine. Erenumab (AMG 334) is the first potent, selective, and competitive human mAb antagonist of CGRP receptor. We report data from two phase I studies assessing safety, pharmacokinetics (PK), pharmacodynamics single multiple administrations erenumab in healthy subjects patients with The results indicate that PK profile nonlinear 1 mg to 70 linear...

10.1002/cpt.799 article EN Clinical Pharmacology & Therapeutics 2017-07-24

Capsaicin-induced dermal blood flow (CIDBF) is a validated biomarker used to evaluate the target engagement of potential calcitonin gene-related peptide-blocking therapeutics for migraine. To characterize pharmacokinetics (PK) and quantify inhibitory effects erenumab (AMG 334) on CIDBF, CIDBF data were pooled from single- multiple-dose study in healthy migraine subjects. Repeated capsaicin challenges DBF measurements performed serum concentrations determined. A population analysis was...

10.1007/s11095-017-2183-6 article EN cc-by Pharmaceutical Research 2017-06-07

In the setting of breast cancer screening, 5-9% needle core biopsies are diagnosed as lesions uncertain malignant potential (B3). The management these is potentially problematic data on their outcome remains limited. our study, we aim to assess screen-detected B3 in a large series validate previous studies and characterize detected after diagnosis. Therefore, results 1,025 women screened over 7-year period (1999-2006) two different regions UK with diagnoses who underwent surgical excision...

10.1002/ijc.25801 article EN International Journal of Cancer 2010-12-02

Gaining full benefits from osteoporosis medications requires long-term treatment. Investigating the real-world persistence of women receiving in UK, we found that most patients stop treatment within a year. To prevent osteoporotic fragility fractures, must be improved. Persistence with therapies has historically been poor. treat this chronic and progressive disease, it is essential receive benefit these medications. We estimated compliance large sample postmenopausal UK. Data were obtained...

10.1007/s00198-019-05228-8 article EN cc-by-nc Osteoporosis International 2019-11-22

To provide updated evidence of the outcome breast lesions uncertain malignant potential (B3) and suspicious malignancy (B4) diagnosed on needle core biopsy (NCB) analyse different types intraductal epithelial atypia.One-hundred forty-nine B3 26 B4 NCBs over a 2-year period (2007-2008) were compared with those previous (1998-2000). The proportion diagnoses increased from 3.1% to 4.5%, positive predictive value (PPV) decreased 25% 10%. Increased diagnosis radial scar reductions in PPV lobular...

10.1111/j.1365-2559.2011.03786.x article EN Histopathology 2011-03-01

Abstract Ectopic varices are defined as portosystemic venous collaterals occurring in the gastrointestinal tract outside of cardio‐esophageal region. Duodenal not routinely encountered by pediatric gastroenterologists. At time this case report, there no consensus guidelines on management bleeding duodenal patients. This is a 14‐year‐old young woman with history multi‐visceral transplantation due to short gut syndrome. The patient had developed near her transplant anastomosis, which were...

10.1002/jpr3.70017 article EN cc-by JPGN Reports 2025-03-17

Introduction:The aim was to compare the accuracy of standard supplementary views and GE digital breast tomosynthesis (DBT) for assessment soft tissue mammographic abnormalities.Methods: Women recalled further abnormalities were recruited received (typically spot compression views) two-view DBT.The added value DBT in process determined by analysing data collected prospectively unblinded radiologists working up cases.Following anonymisation cases, there also a retrospective multireader...

10.1186/bcr3757 article EN cc-by Breast Cancer Research 2015-11-05

To assess whether vacuum-assisted excision (VAE) is a safe alternative to surgery in the treatment of breast lesions uncertain malignant potential (B3) which no atypia present on needle core biopsy (NCB). Forty two VAE procedures were performed for B3 lesions. Twenty four (57%) papillary Eighteen (43%) radial scars. Two patients (4.7%) upgraded carcinoma at VAE. with went develop cancer same (at 24 and 41 months post VAE). No developed scar group. Eight (19%) had - carcinoma, scars missed...

10.1016/j.breast.2008.08.005 article EN cc-by-nc-nd The Breast 2008-10-02

Evolocumab binds PCSK9, increasing low-density lipoprotein cholesterol (LDL-C) receptors and lowering LDL-C. Target-mediated evolocumab elimination is attributable to PCSK9 binding. As circulating LDL-C levels are primarily regulated by the liver, we compared pharmacokinetics, pharmacodynamics, safety in individuals with without hepatic impairment. An open-label, parallel-group study evaluated pharmacokinetics of hepatic-impaired (Child-Pugh Class A or B) healthy adults. Participants were...

10.1002/jcph.832 article EN cc-by-nc-nd The Journal of Clinical Pharmacology 2016-09-26

Sonographic measurement of fetal humeral soft tissue thickness (STT) was performed in 93 women with gestational diabetes mellitus during the third trimester. STT measurements revealed accelerated growth large for age infants at 31 wk gestation. This new proved to be most accurate predictor excessive size compared other standard ultrasound parameters (sensitivity 82%, specificity 95%, positive predictive value 90%). Asymmetrical more evident utero. Humeral may distinguish fetuses truncal...

10.2337/diab.40.2.s66 article EN Diabetes 1991-12-01

Several studies have shown that darbepoetin alfa, an erythropoiesis-stimulating agent (ESA), can reduce transfusions and increase hemoglobin (Hb) levels in patients with chemotherapy-induced anemia (CIA). Recent safety concerns, however, prompted changes to ESA product information. In the European Union United States, therapy initiation for CIA is now recommended at a Hb level ≤10 g/dL. The present exploratory analysis examined how this may impact patient care. Data from phase 3 randomized...

10.1186/1471-2407-9-311 article EN cc-by BMC Cancer 2009-09-03

Drug-disease interactions involving therapeutic proteins that target cytokines and potentially impact cytochrome P450 (CYP) enzymes have been of increased interest to drug regulatory agencies industry sponsors in recent years. This parallel-group open-label study evaluated the effects monoclonal antibody denosumab, an inhibitor cytokine RANKL, on pharmacokinetics probe CYP3A4 substrate midazolam postmenopausal women with osteoporosis. The a 2 mg oral dose was days 1 16. Subjects Group A...

10.1002/prp2.33 article EN cc-by-nc-nd Pharmacology Research & Perspectives 2014-03-13

The effects of cholesterol-lowering drugs, including those that reduce cholesterol synthesis (statins) and absorption (ezetimibe), on are well understood. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors a novel class drugs robustly LDL-cholesterol (LDL-C), but little is known about their synthesis. We evaluated how treatment with evolocumab, fully human monoclonal IgG2 antibody to PCSK9, affects markers by measuring these in patients from an evolocumab clinical trial. At 2...

10.1194/jlr.p071704 article EN cc-by Journal of Lipid Research 2016-10-06

Objective: To compare the accuracy of standard supplementary views and GE digital breast tomosynthesis (DBT) for assessment soft-tissue mammographic abnormalities. Methods: Women recalled further abnormalities were recruited received (typically spot compression views) two-view DBT. The added value DBT in process was determined by analysing data collected prospectively radiologists working up cases. Following anonymization cases, there also a retrospective multireader review. readers first...

10.1259/bjr.20150735 article EN British Journal of Radiology 2015-11-11

CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) ± rituximab [(±R)CHOP] is the current standard of care for aggressive non-Hodgkin lymphoma (NHL). Anemia resulting from chemotherapy can be treated with erythropoiesis-stimulating agents (ESAs). As part observational IMPACT NHL study, data were collected on ESA use and anemia-related outcomes in 1829 adults receiving (±R)CHOP-14 or (±R)CHOP-21. Overall, 33% patients anemic during chemotherapy. Older age, lower baseline...

10.3109/10428194.2011.557166 article EN Leukemia & lymphoma/Leukemia and lymphoma 2011-02-21
Coming Soon ...